id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S16807 R70520 |
Ertürk Çetin (Epilepsy) (Levetiracetam), 2024 | At least one minor anomaly | throughout pregnancy | prospective cohort | exposed to other treatment, sick | Adjustment: No | 3.33 [0.59;18.89] C | 12/18 3/8 | 15 | 18 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15842 R65222 |
Bromley (Levetiracetam) (Controls exposed to LTG), 2023 | Minor congenital anomaly | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.36 [0.07;1.75] C excluded (control group) |
2/70 8/106 | 10 | 70 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15843 R65235 |
Bromley (Levetiracetam) (Controls unexposed, sick), 2023 | Minor congenital anomaly | during pregnancy (anytime or not specified) excluded | prospective cohort | unexposed, sick | Adjustment: No |
2.32 [0.21;26.19] C excluded (exposition period) |
2/70 1/80 | 3 | 70 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12502 R47878 |
Mari (Levetiracetam), 2022 | Minor congenital malformations | throughout pregnancy | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 2.03 [0.08;54.83] C | 1/17 0/11 | 1 | 17 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S16700 R70271 |
Alsaadi (Controls exposed to LTG), 2020 | Minor congenital malformations | 1st trimester | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.09 [0.00;2.46] C excluded (control group) |
0/38 1/12 | 1 | 38 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S16701 R70275 |
Alsaadi (Controls unexposed sick), 2020 | Minor congenital malformations | 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No | 0.95 [0.02;49.01] C | 0/38 0/36 | 0 | 38 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 2.57 [0.62;10.76] | 16 | 73 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Epilepsy) (Levetiracetam; 2: Levetiracetam; 3: Controls unexposed sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 16700, 15842